for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IGM Biosciences Inc

IGMS.OQ

Latest Trade

60.92USD

Change

1.87(+3.17%)

Volume

56,568

Today's Range

58.99

 - 

62.78

52 Week Range

18.89

 - 

89.73

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
59.05
Open
59.16
Volume
56,568
3M AVG Volume
3.55
Today's High
62.78
Today's Low
58.99
52 Week High
89.73
52 Week Low
18.89
Shares Out (MIL)
30.59
Market Cap (MIL)
1,810.19
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 IGM Biosciences Inc Earnings Release

Latest Developments

More

IGM Biosciences Announces Second Quarter 2020 Financial Results And Provides Corporate Update

IGM Biosciences Reports Quarterly Loss Per Share Of $0.58

Igm Biosciences Reports Q4 Net Loss Of $14.8 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).

Industry

Biotechnology & Drugs

Contact Info

325 E Middlefield Rd

MOUNTAIN VIEW, CA

94043-4003

United States

+1.650.9657873

http://igmbio.com/

Executive Leadership

Michael D. Loberg

Independent Chairman of the Board

Fred M. Schwarzer

President, Chief Executive Officer, Director

Misbah Tahir

Chief Financial Officer

Bruce Keyt

Chief Scientific Officer

Daniel Shinyu Chen

Chief Medical Officer

Key Stats

1.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-4.800

2020(E)

-2.679
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.73
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.29
Return on Equity (TTM)
-44.28

Latest News

Latest News

BRIEF-IGM Biosciences Reports Quarterly Loss Per Share Of $0.58

* IGM BIOSCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-IGM Biosciences, Atreca, Beigene To Collaborate To Help Address Covid-19

* IGM BIOSCIENCES INC - ATRECA, INC. BEIGENE, LTD. AND IGM BIOSCIENCES, INC. ANNOUNCED THEIR PLANS TO COLLABORATE TO HELP ADDRESS COVID-19 PANDEMIC

BRIEF-Igm Biosciences Reports Q4 Net Loss Of $14.8 Mln

* IGM BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up